Skip to main content
Log in

Zoledronic acid

Treatment option for Gorham-Stout disease

Zoledronsäure

Behandlungsoption für das Gorham-Stout-Syndrom

  • Kasuistik
  • Published:
Der Orthopäde Aims and scope Submit manuscript

Abstract

Gorham-Stout disease is a rare bone resorption disease, the etiology and prognosis of which is uncertain but it is thought to be benign. It can involve one or more bones and can cause pain, swelling, deformity and fractures in affected bones. Diagnosis is made with a combination of clinical, radiological and histopathological examinations once other causes of osteolysis have been excluded. Due to its rarity, there is no standard therapeutic approach.

Zusammenfassung

Das Gorham-Stout-Syndrom ist eine seltene Erkrankung, bei der es zu einem Knochenabbau kommt. Ätiologie und Prognose sind ungewiss, aber es gilt als benigne. Es kann ein oder mehrere Knochen betreffen, dabei kann es zu Schmerzen, Schwellungen, Deformitäten und Frakturen in den betroffenen Knochen kommen. Die Diagnose wird anhand einer Kombination aus klinischen, radiologischen und histopathologischen Untersuchungen gestellt, sofern andere Ursachen für die Osteolyse ausgeschlossen wurden. Aufgrund seiner Seltenheit gibt es keine Standardtherapie für diese Erkrankung.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Abbreviations

ALP:

Alkaline phosphatase

AP:

Anteroposterior

CT:

Computed tomography

GSD:

Gorham-Stout disease

MM:

Multiple myeloma

PET-CT:

Positron emission tomography-CT

PTH:

Parathyroid hormone

VEGF:

Vascular endothelial growth factor

ZA:

Zoledronic acid

References

  1. Heritier S, Donadieu J (2012) Gorham’s disease and intra-osseous vascular abnormalities. Bull Cancer 99(5):599–604

    Article  Google Scholar 

  2. Gorham LW, Stout AP (1955) Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis. J Bone Joint Surg Am 37(5):985–1004

    Article  Google Scholar 

  3. Tolis K, Triantafyllopoulos IK, Tournis S, Papaioannou NA (2016) Gorham-Stout disease of the pelvis: Seven years follow up with complete radiological evaluation. J Musculoskelet Neuronal Interact 16(1):79–82

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Sahoo RK, Jagannathan B, Palanichamy G, Natarajan V (2012) Anaesthetic consideration in patients with Gorham’s syndrome: a case report and review of the literature. Indian J Anaesth 56(4):391–393

    Article  Google Scholar 

  5. Yoo SY, Hong SH, Chung HW, Choi JA, Kim CJ, Kang HS (2002) MRI of Gorham’s disease: findings in two cases. Skeletal Radiol 31(5):301–306

    Article  Google Scholar 

  6. Mawk JR, Obukhov SK, Nichols WD, Wynne TD, Odell JM, Urman SM (1997) Successful conservative management of Gorham disease of the skull base and cervical spine. Childs Nerv Syst 13(11–12):622–625

    Article  CAS  Google Scholar 

  7. Patel DV (2005) Gorham’s disease or massive osteolysis. Clin Med Res 3:65–74

    Article  Google Scholar 

  8. Angelini A, Mavrogenis AF, Rimondi E, Rossi G, Ruggieri P (2017) Current concepts for the diagnosis and management of eosinophilic granuloma of bone. J Orthop Traumatol 18:83–90

    Article  Google Scholar 

  9. Mollee P (2009) Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev 30(3):93–103

    PubMed  PubMed Central  Google Scholar 

  10. Nikolaou VS, Chytas D, Korres D, Efstathopoulos N (2014) Vanishing bone disease (Gorham-Stout syndrome): a review of a rare entity. World J Orthop 5(5):694–698

    Article  Google Scholar 

  11. Yerganyan VV, Body JJ, De Saint Aubain N, Gebhart M (2015) Gorham-Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid. J Bone Oncol 4(2):42–46

    Article  CAS  Google Scholar 

  12. Lehmann G, Pfeil A, Bottcher J et al (2009) Benefit of a 17-year long-term bisphosphonate therapy in a patient with GorhamStout syndrome. Arch Orthop Trauma Surg 129:967–972

    Article  Google Scholar 

  13. Hammer F, Kenn W, Wesselmann U et al (2005) Gorham-Stout disease—stabilization during bisphosphonate treatment. J Bone Miner Res 20:350–353

    Article  Google Scholar 

  14. Stefanidou M, Ioannidou D, Panayotides J et al (2004) Cutaneous vascular malformation associated with osteolysis or Gorham’s sign. Int J Dermatol 43:958–961

    Article  CAS  Google Scholar 

  15. Avelar RL, Martins VB, Antunes AA, de Oliveira Neto PJ, Andrade ES (2010) Use of zoledronic acid in the treatment of Gorham’s disease. Int J Pediatr Otorhinolaryngol 74(3):319–322

    Article  Google Scholar 

  16. Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R (2005) Treatment of Gorham’s disease with zoledronic acid. Oral Oncol 41:747–750

    Article  CAS  Google Scholar 

  17. Kuriyama DK, McElligott SC, Glaser DW, Thompson KS (2010) Treatment of Gorham-Stout disease with zoledronic acid and interferon-α: a case report and literature review. J Pediatr Hematol Oncol 32(8):579–584

    Article  Google Scholar 

  18. Cramer SL, Wei S, Merrow AC, Pressey JG (2016) Gorham-stout disease successfully treated with Sirolimus and Zoledronic acid therapy. J Pediatr Hematol Oncol 38(3):e129–e132

    Article  CAS  Google Scholar 

  19. Ocarino NM, Serakides R (2006) Effect of the physical activity on normal bone and on the osteoporosis prevention and treatment. Rev Bras Med Esporte 12(3):149–152

    Article  Google Scholar 

  20. Ellati R, Attili A, Haddad H, Al-Hussaini M, Shehadeh A (2016) Novel approach of treating Gorham-Stout disease in the humerus—Case report and review of literature. Eur Rev Med Pharmacol Sci 20(3):426–432

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ozge Gulsum Illeez.

Ethics declarations

Conflict of interest

O.G. Illeez, K. Ozkan, F.U. Ozkan, A.B. Bostan, F. Akpinar, B. Bilgic and I. Aktas declare that they have no competing interests.

This article does not contain any studies with human participants or animals performed by any of the authors. For images or other information within the manuscript which identify patients, consent was obtained from them and/or their legal guardians.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Illeez, O.G., Ozkan, K., Ozkan, F.U. et al. Zoledronic acid. Orthopäde 47, 1032–1035 (2018). https://doi.org/10.1007/s00132-018-3655-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00132-018-3655-z

Keywords

Schlüsselwörter

Navigation